In the following, these subjects are explained in the context of the principle strategies in adjuvant therapy of EBC.There were no clinically applicable variations as compared to 2011 apart from new information and new suggestions with regard to the treatment with bisphosphonates and denosumab (see part ‘Bisphosphonates and RANKL Antibody Denosum